(R)-N-[5-[1-hydroxy-2-[[1-(3,4-dimethoxyphenyl)-2-phenylethyl]amino]ethyl]-2-(hydroxy)phenyl]methanesulfonamide | 246262-41-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 石蒜科生物碱
• 英文名称: (R)-N-[5-[1-hydroxy-2-[[1-(3,4-dimethoxyphenyl)-2-phenylethyl]amino]ethyl]-2-(hydroxy)phenyl]methanesulfonamide
• 英文别名: N-[5-[2-[1-(3,4-Dimethoxyphenyl)-2-phenylethylamino]-1(R)-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide；N-[5-[(1R)-2-[[1-(3,4-dimethoxyphenyl)-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide
• CAS: 246262-41-9
• 化学式: C₂₅H₃₀N₂O₆S
• 分子量: 486.589
• InChiKey: PCYFGGBXPASOJI-AKRCKQFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF, AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Hayashi Ryoji

  公开号：US20100099769A1

  公开（公告）日：2010-04-22

  The benzylamine derivative represented by the formula below and a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutical containing the derivative or the pharmaceutically acceptable acid addition salt thereof, and a therapeutic or prophylactic agent for pollakiuria or urinary incontinence containing the derivative or the pharmaceutically acceptable acid addition salt thereof are provided. The benzylamine derivative of the present invention and the pharmaceutically acceptable acid addition salt thereof have less possibility of occurrence of side effects than known compounds, and show a better therapeutic effect against pollakiuria or urinary incontinence, so that they can be used as excellent therapeutic or prophylactic agents for pollakiuria or urinary incontinence.

  本发明提供了以下式子所代表的苄基胺衍生物及其药学上可接受的酸加成盐，以及含有该衍生物或其药学上可接受的酸加成盐的制药组合物，以及用于治疗或预防频尿或尿失禁的治疗剂或预防剂，该治疗剂或预防剂含有该衍生物或其药学上可接受的酸加成盐。本发明的苄基胺衍生物及其药学上可接受的酸加成盐比已知化合物的副作用发生可能性更小，并且对于频尿或尿失禁具有更好的治疗效果，因此可以作为优秀的治疗或预防频尿或尿失禁的治疗剂或预防剂。
• Use of beta 3 adrenergic receptor agonists in the treatment of dysuria
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1382333A2

  公开（公告）日：2004-01-21

  The application relates to the use of a β3 adrenergic receptor agonist selected from the group consisting of formulas (IV),(V),(VI),(VII) and (VIII) for the manufacture of a medicament for the prophylactic and/or the therapeutic treatment of dysuria. In the above formulae, the various groups, substituents and variables have the meanings given in the description.

  本申请涉及选自式(IV)、(V)、(VI)、(VII)和(VIII)组成的组中的β3 肾上腺素能受体激动剂的用途。 用于制造预防和/或治疗排尿困难的药物。在上式中，各基团、取代基和变量具有说明中给出的含义。
• PROPANOLAMINE DERIVATIVES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1070046A1

  公开（公告）日：2001-01-24
• US6495546B1
  申请人：——

  公开号：US6495546B1

  公开（公告）日：2002-12-17
• US8148427B2
  申请人：——

  公开号：US8148427B2

  公开（公告）日：2012-04-03